{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.48","upperLimit":"9.79","value":"6.24"},{"groupId":"OG001","lowerLimit":"2.79","upperLimit":"19.15","value":"6.93"},{"groupId":"OG002","lowerLimit":"1.84","upperLimit":"5.52","value":"3.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"72"}],"units":"Participants"}],"description":"Progression free survival (PFS) is defined as the time between date of randomization and date of progression or death, whichever occurs first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Subjects who did not progress or die were censored on the date of their last efficacy assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"3mg/kg of nivolumab","id":"OG000","title":"Nivolumab Monotherapy (Expansion)"},{"description":"3 mg/kg of nivolumab and\n\n1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W","id":"OG001","title":"Nivolumab + Ipilimumab"},{"description":"3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W","id":"OG002","title":"Nivolumab + Lirilumab"}],"paramType":"MEDIAN","populationDescription":"All Treated Participants with available measurements","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of progression or death, whichever occurs first (up to approximately 24 months)","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}